Speer Claudius, Morath Christian, Töllner Maximilian, Buylaert Mirabel, Göth Daniel, Nusshag Christian, Kälble Florian, Schaier Matthias, Grenz Julia, Kreysing Martin, Reichel Paula, Hidmark Asa, Ponath Gerald, Schnitzler Paul, Zeier Martin, Süsal Caner, Klein Katrin, Benning Louise
Department of Nephrology, University of Heidelberg, Heidelberg, Germany.
Molecular Medicine Partnership Unit Heidelberg, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Front Med (Lausanne). 2021 Aug 17;8:721286. doi: 10.3389/fmed.2021.721286. eCollection 2021.
Seroconversion rates following infection and vaccination are lower in dialysis patients compared to healthy controls. There is an urgent need for the characterization of humoral responses and success of a single-dose SARS-CoV-2 vaccination in previously infected dialysis patients. We performed a dual-center cohort study comparing three different groups: 25 unvaccinated hemodialysis patients after PCR-confirmed COVID-19 (Group 1), 43 hemodialysis patients after two-time BNT162b2 vaccination without prior SARS-CoV-2 infection (Group 2), and 13 single-dose vaccinated hemodialysis patients with prior SARS-CoV-2 infection (Group 3). Group 3 consists of seven patients from Group 1 and 6 additional patients with sera only available after single-dose vaccination. Anti-S1 IgG, neutralizing antibodies, and antibodies against various SARS-CoV-2 protein epitopes were measured 3 weeks after the first and 3 weeks after the second vaccination in patients without prior SARS-CoV-2 infection, 6 weeks after the onset of COVID-19 in unvaccinated patients, and 3 weeks after single-dose vaccination in patients with prior SARS-CoV-2 infection, respectively. Unvaccinated patients after COVID-19 showed a significantly higher neutralizing antibody capacity than two-time vaccinated patients without prior COVID-19 [median (IQR) percent inhibition 88.0 (71.5-95.5) vs. 50.7 (26.4-81.0); = 0.018]. After one single vaccine dose, previously infected individuals generated 15- to 34-fold higher levels of anti-S1 IgG than age- and dialysis vintage-matched unvaccinated patients after infection or two-time vaccinated patients without prior SARS-CoV-2 infection with a median (IQR) index of 274 (151-791) compared to 18 (8-41) and 8 (1-21) (for both < 0.001). With a median (IQR) percent inhibition of 97.6 (97.2-98.9), the neutralizing capacity of SARS-CoV-2 antibodies was significantly higher in single-dose vaccinated patients with prior SARS-CoV-2 infection compared to other groups (for both < 0.01). Bead-based analysis showed high antibody reactivity against various SARS-CoV-2 spike protein epitopes after single-dose vaccination in previously infected patients. In conclusion, single-dose vaccination in previously infected dialysis patients induced a strong and broad antibody reactivity against various SARS-CoV-2 spike protein epitopes with high neutralizing capacity.
与健康对照相比,透析患者感染和接种疫苗后的血清转化发生率较低。迫切需要了解既往感染过的透析患者的体液免疫反应特征以及单剂量接种SARS-CoV-2疫苗的效果。我们进行了一项双中心队列研究,比较了三个不同组:25例PCR确诊COVID-19后未接种疫苗的血液透析患者(第1组)、43例既往未感染SARS-CoV-2且接种两剂BNT162b2疫苗的血液透析患者(第2组)以及13例既往感染过SARS-CoV-2且单剂量接种疫苗的血液透析患者(第3组)。第3组由7例来自第1组的患者和另外6例仅在单剂量接种疫苗后才有血清的患者组成。在未感染过SARS-CoV-2的患者中,分别在首次接种后3周和第二次接种后3周测量抗S1 IgG、中和抗体以及针对各种SARS-CoV-2蛋白表位的抗体;在未接种疫苗的患者中,在COVID-19发病后6周测量;在既往感染过SARS-CoV-2的患者中,在单剂量接种疫苗后3周测量。COVID-19后未接种疫苗的患者显示出比既往未感染COVID-19且接种两剂疫苗者显著更高中和抗体能力[中位值(四分位间距)抑制百分比88.0(71.5 - 95.5)对50.7(26.4 - 81.0);P = 0.018]。单剂量接种疫苗后,既往感染过的个体产生的抗S1 IgG水平比年龄和透析病程匹配的感染后未接种疫苗患者或既往未感染SARS-CoV-2且接种两剂疫苗患者高15至34倍,中位值(四分位间距)指数为274(151 - 791),而后者分别为18(8 - 41)和8(1 - 21)(两者P均<0.001)。既往感染过SARS-CoV-2且单剂量接种疫苗患者的SARS-CoV-2抗体中和能力中位值(四分位间距)抑制百分比为97.6(97.2 - 98.9),与其他组相比显著更高(两者P均<0.01)。基于微珠的分析显示,既往感染过的患者单剂量接种疫苗后对各种SARS-CoV-2刺突蛋白表位具有高抗体反应性。总之,既往感染过的透析患者单剂量接种疫苗可诱导针对各种SARS-CoV-2刺突蛋白表位产生强烈且广泛的抗体反应,并具有高中和能力。